Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Daridorexant
Therapeutic Area : Sleep
Study Phase : Approved
Recipient : Idorsia Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The study met both primary and secondary efficacy endpoint measures ACT-541468 (Daridorexant) significantly improved sTST from baseline compared to placebo at 28 days (p<0.001 for 50 mg, p=0.042 for 25 mg).
Brand Name : ACT-541468
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 03, 2022
Lead Product(s) : Daridorexant
Therapeutic Area : Sleep
Highest Development Status : Approved
Recipient : Idorsia Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Macrogol
Therapeutic Area : Gastroenterology
Study Phase : Approved
Recipient : EA Pharma
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : MOVICOL® HD is a high dose formulation of existing “MOVICOL® LD”, the first polyethylene glycol indicated for treatment of chronic constipation1) in Japan. MOVICOL® HD contains the same active ingredients in double the quantity of MOVICOL® LD per...
Brand Name : Movicol HD
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 20, 2022
Lead Product(s) : Macrogol
Therapeutic Area : Gastroenterology
Highest Development Status : Approved
Recipient : EA Pharma
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?
Reset All
